Gregory W Roloff1, Lucy A Godley2,3, Michael W Drazer4,5. 1. Department of Medicine, Loyola University Medical Center, Maywood, IL, USA. 2. Section of Hematology/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. 3. Department of Human Genetics, The University of Chicago, Chicago, IL, USA. 4. Section of Hematology/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. mdrazer@medicine.bsd.uchicago.edu. 5. Department of Human Genetics, The University of Chicago, Chicago, IL, USA. mdrazer@medicine.bsd.uchicago.edu.
Abstract
PURPOSE: To determine the degree of testing consistency among commercially available diagnostic assays for hereditary hematopoietic malignancies (HHMs). METHODS: Next-generation sequencing assays designed for the diagnosis of HHMs were studied to determine which genes were sequenced, their ability to detect variant types relevant for HHMs, and clinical-grade characteristics such as price, turnaround time, and tissue types accepted. RESULTS: Commercial assays varied in price (USD 250-4702), number of genes sequenced (12-73), and average turnaround time (14-42 days). A number of nongermline tissue types were accepted despite the tests being designed for germline diagnostic purposes. Multiple genes with well-characterized roles in HHM pathogenesis were omitted from more than one-third of panels intended for the evaluation of HHMs. Only 4 of 82 genes were consistently covered across all HHM diagnostic panels. The assays were highly variable in their sensitivity for structural alterations relevant to HHMs, such as copy-number variants. CONCLUSION: A high degree of diagnostic heterogeneity exists among commercially available HHM diagnostic assays. Many of these assays are incapable of detecting the full spectrum of HHM-associated variants, leaving patients vulnerable to the consequences of underdiagnosis, missed opportunities for screening, and the potential for donor-derived malignancies.
PURPOSE: To determine the degree of testing consistency among commercially available diagnostic assays for hereditary hematopoietic malignancies (HHMs). METHODS: Next-generation sequencing assays designed for the diagnosis of HHMs were studied to determine which genes were sequenced, their ability to detect variant types relevant for HHMs, and clinical-grade characteristics such as price, turnaround time, and tissue types accepted. RESULTS: Commercial assays varied in price (USD 250-4702), number of genes sequenced (12-73), and average turnaround time (14-42 days). A number of nongermline tissue types were accepted despite the tests being designed for germline diagnostic purposes. Multiple genes with well-characterized roles in HHM pathogenesis were omitted from more than one-third of panels intended for the evaluation of HHMs. Only 4 of 82 genes were consistently covered across all HHM diagnostic panels. The assays were highly variable in their sensitivity for structural alterations relevant to HHMs, such as copy-number variants. CONCLUSION: A high degree of diagnostic heterogeneity exists among commercially available HHM diagnostic assays. Many of these assays are incapable of detecting the full spectrum of HHM-associated variants, leaving patients vulnerable to the consequences of underdiagnosis, missed opportunities for screening, and the potential for donor-derived malignancies.
Entities:
Keywords:
cancer risk; germline; hematopoietic malignancies; inherited leukemia; panel testing
Authors: Michael W Drazer; Sabah Kadri; Madina Sukhanova; Sushant A Patil; Allison H West; Simone Feurstein; Dalein A Calderon; Matthew F Jones; Caroline M Weipert; Christopher K Daugherty; Adrián A Ceballos-López; Gordana Raca; Mark W Lingen; Zejuan Li; Jeremy P Segal; Jane E Churpek; Lucy A Godley Journal: Blood Adv Date: 2018-01-23
Authors: Nicolas Duployez; Christophe Willekens; Isabelle Plo; Alice Marceau-Renaut; Stéphane de Botton; Laurène Fenwarth; Thomas Boyer; Guillemette Huet; Olivier Nibourel; Christian Rose; Brigitte Nelken; Bruno Quesnel; Claude Preudhomme Journal: Blood Date: 2019-12-26 Impact factor: 22.113
Authors: Maya Lewinsohn; Anna L Brown; Luke M Weinel; Connie Phung; George Rafidi; Ming K Lee; Andreas W Schreiber; Jinghua Feng; Milena Babic; Chan-Eng Chong; Young Lee; Agnes Yong; Graeme K Suthers; Nicola Poplawski; Meryl Altree; Kerry Phillips; Louise Jaensch; Miriam Fine; Richard J D'Andrea; Ian D Lewis; Bruno C Medeiros; Daniel A Pollyea; Mary-Claire King; Tom Walsh; Siobán Keel; Akiko Shimamura; Lucy A Godley; Christopher N Hahn; Jane E Churpek; Hamish S Scott Journal: Blood Date: 2015-12-28 Impact factor: 22.113
Authors: Xi Luo; Simone Feurstein; Shruthi Mohan; Christopher C Porter; Sarah A Jackson; Sioban Keel; Michael Chicka; Anna L Brown; Chimene Kesserwan; Anupriya Agarwal; Minjie Luo; Zejuan Li; Justyne E Ross; Panagiotis Baliakas; Daniel Pineda-Alvarez; Courtney D DiNardo; Alison A Bertuch; Nikita Mehta; Tom Vulliamy; Ying Wang; Kim E Nichols; Luca Malcovati; Michael F Walsh; Lesley H Rawlings; Shannon K McWeeney; Jean Soulier; Anna Raimbault; Mark J Routbort; Liying Zhang; Gabriella Ryan; Nancy A Speck; Sharon E Plon; David Wu; Lucy A Godley Journal: Blood Adv Date: 2019-10-22
Authors: Chantana Polprasert; Isabell Schulze; Mikkael A Sekeres; Hideki Makishima; Bartlomiej Przychodzen; Naoko Hosono; Jarnail Singh; Richard A Padgett; Xiaorong Gu; James G Phillips; Michael Clemente; Yvonne Parker; Daniel Lindner; Brittney Dienes; Eckhard Jankowsky; Yogen Saunthararajah; Yang Du; Kevin Oakley; Nhu Nguyen; Sudipto Mukherjee; Caroline Pabst; Lucy A Godley; Jane E Churpek; Daniel A Pollyea; Utz Krug; Wolfgang E Berdel; Hans-Ulrich Klein; Martin Dugas; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Kenichi Yoshida; Seishi Ogawa; Carsten Müller-Tidow; Jaroslaw P Maciejewski Journal: Cancer Cell Date: 2015-04-23 Impact factor: 31.743
Authors: Yasunobu Nagata; Satoshi Narumi; Yihong Guan; Bartlomiej P Przychodzen; Cassandra M Hirsch; Hideki Makishima; Hirohito Shima; Mai Aly; Victor Pastor; Teodora Kuzmanovic; Tomas Radivoyevitch; Vera Adema; Hassan Awada; Kenichi Yoshida; Samuel Li; Francesc Sole; Rabi Hanna; Babal K Jha; Thomas LaFramboise; Seishi Ogawa; Mikkael A Sekeres; Marcin W Wlodarski; Jörg Cammenga; Jaroslaw P Maciejewski Journal: Blood Date: 2018-10-15 Impact factor: 25.476